Peptide-oligonucleotide conjugates represent an emerging approach for targeted delivery of nucleic acid therapeutics. By conjugating oligonucleotides (siRNA, antisense, aptamers) to targeting peptides, these conjugates enable cell-specific delivery, overcoming one of the major barriers to nucleic acid therapy.
The peptide component of the conjugate serves as a homing device, binding to receptors that are overexpressed on target cells. This targeting reduces off-target effects and enables lower dosing, improving the therapeutic index. Common targeting peptides include those that bind to integrins, growth factor receptors, and cell-penetrating peptides that enhance cellular uptake.
The oligonucleotide component provides the therapeutic effect. siRNA conjugates can silence disease-causing genes, antisense oligonucleotides can modulate splicing or inhibit translation, and aptamers can bind and inhibit specific targets. The choice of oligonucleotide depends on the therapeutic target and mechanism of action.
Key challenges in peptide-oligonucleotide conjugate development include achieving efficient conjugation while maintaining the activity of both components, ensuring stability in biological fluids, and optimizing cellular uptake and intracellular trafficking. Advances in conjugation chemistry and formulation are addressing these challenges.
At PeptideHub, we provide custom peptide-oligonucleotide conjugation services with defined stoichiometry and purification. Our experienced team can design and execute conjugation strategies for diverse applications, from research tools to therapeutic candidates. We provide high-quality conjugates with full analytical documentation, supporting your research and development programs in this emerging field.